US40637H1095
US40637H1095
Halozyme Therapeutics, Inc.
Loading chart...
Valuation & History
Quarterly trend of key valuation metrics
| Metric | Current (TTM) TTM Baseline | Q2 '26 30.06.2026 | Q1 '26 31.03.2026 | Q4 '25 31.12.2025 |
|---|---|---|---|---|
Market & Enterprise Value | ||||
Market Cap | 12.53B EUR | 8.93B EUR | 7.66B EUR | 7.93B EUR |
Enterprise Value | 14.41B EUR | 10.91B EUR | 9.5B EUR | 9.94B EUR |
Valuation Multiples | ||||
Trailing P/E | 32.29x | 21.58x | 21.96x | 39.87x |
Forward P/E | 10.39x | -- | -- | -- |
Price to Sales | 7.53x | 5.37x | 5.08x | 7x |
Price to Book | 87.7x | 62.18x | 34.88x | 162.39x |
EV/Revenue | 8.66x | 6.56x | 6.29x | 8.78x |
EV/EBITDA | 13.72x | 10.43x | 10.03x | 13.64x |
Price to FCF (P/FCF) | 37.15x | 17.22x | 20.16x | 38.94x |
EV/FCF | 42.73x | 21.04x | 24.99x | 48.81x |
FCF Yield | 2.69% | 5.81% | 4.96% | 2.57% |